



ARE YOU PREPARED TO HELP IN A HEARTBEAT?

It happens in a split second: a person collapses – the victim of sudden cardiac arrest – and the clock starts ticking. You call for help and medical personnel are on their way. But precious seconds are racing by. The victim's best chance for survival depends on immediate CPR and a rescuer with an automated external defibrillator (AED).



According to the ANZCOR Guidelines for Resuscitation, time to defibrillation and high quality CPR are the two most important factors to improving sudden cardiac arrest survival rates.¹

THE POWER TO HELP

At St John, we strive to provide easy to use, reliable AEDs with proven technology to enable bystanders to act quickly, appropriately and with confidence in sudden cardiac arrest emergencies.

The St John Ambulance G5 guides you through the process of performing high-quality CPR and will, if needed, deliver a potentially lifesaving shock to the heart. With a St John Ambulance G5 and quick action, you could help save lives.





READY FOR THE RESCUE

The survival rate from sudden cardiac arrest is less than 6.4% worldwide.² According to the ANZCOR Guidelines for Resuscitation, high-quality CPR, along with early defibrillation, can help improve SCA survival rates.¹

The St John Ambulance G5 is the only AED to combine real-time CPR feedback with user-paced rescue prompting. It also performs automatic self-testing to ensure the device is always Rescue Ready[®].





Real-Time CPR Feedback

The St John Ambulance G5 uses Intellisense™ CPR (ICPR) technology to monitor CPR chest compressions, providing rescuers with a metronome and distinct corrective audible and visual CPR prompts: "Press Slower", "Press Faster", "Press Softer", and, "Press Harder and Fully Release".



User-Paced Rescue Prompts

RescueCoach™ voice and on screen text prompts guide users step-by-step through the rescue process. The AED recognises actions taken and ensures that the rescuer completes every critical task before moving on to the next.



Rescue Ready® and Rugged

The St John Ambulance G5 is durable and performs comprehensive self-testing to ensure it is ready to rescue. Studies have shown that approximately 46% of AED failures are due to pad, pad connector, or battery power problems.³ The St John Ambulance G5 self-tests to detect and help prevent these issues. Coupled with military-tested ruggedness and an IP55 against dust and water, you will be ready for a rescue.



Proven Technology

The St John Ambulance G5 analyses the patient's heart rhythm in seconds and delivers a customised shock for each patient.

The St John Ambulance G5 combines ease of use, reliability and advanced technology to support experienced rescuers through to first-time responders during a sudden cardiac arrest event.



St John Ambulance G5



The St John Ambulance G5 with RescueCoach™ guides you through the entire rescue with clear voice and text prompts, allowing you to finish each critical task at your own pace. When a shockable heart rhythm is detected the device will deliver a shock as needed.

St John Ambulance is Australia's leading provider of first aid services, training and equipment and is a trusted brand with over 137 years of experience.

shop.stjohn.org.au/defibrillators • 1300 360 455

© St John Ambulance Australia Ltd, 2021. St John first aid protocols are for the Australian market only. All care has been taken in preparing the information but St John takes no responsibility for its use by other parties or individuals. This information is not a substitute for first aid training. St John recommends attending first aid training courses. Not for commercial distribution.

¹ ANZCOR Guideline 11.2 - Protocols for Adult Advanced Life Support.

² Resuscitation Journal; Incidence and outcome of out-of-hospital cardiac arrests in the COVID-19 era: A systematic review and meta-analysis, Volume 157, P248-258, December 01, 2020; https://www.resuscitationjournal.com/article/S0300-9572(20)30533-5/fulltext

³ Annals Emergency Medicine; Analysis of Automated External Defibrillator Device Failures, Reported to the Food and Drug Administration, Volume 59, no. 2, February 2012